Overview

Patient Perception Study for AL-4943A

Status:
Completed

Trial end date:
2011-10-01

Target enrollment:

Participant gender:

Summary

To evaluate patient perceptions of Al-4943 in subjects with allergic conjunctivitis previously treated with a topical ocular anti-allergy leukotriene-release inhibitor medication.

Phase:

Phase 4

Details

Lead Sponsor:

Alcon Research

Treatments:

Olopatadine Hydrochloride